1. SWEDRES 2004 Figures and Tables

2. SWEDRES 2004 Table 3.1.1 Total use of antobacterial drugs in Sweden 1995-2004 DDD/1000/day Data source: The National Corporation of Swedish Pharmacies

3. SWEDRES 2004

10. Table 3.1.3. Use of tetracyclines, out-patient care 2004 DDD/1000/day and prescriptions/1000/year respectively

11. SWEDRES 2004

18. Table 3.1.4. Total use of antibiotics within hospital care 1995-2004 DDD/1000/day.

19. SWEDRES 2004

25. Swedres 2004, Figure 4.1. Annual PRP incidence 1997-2004. 0 2 4 6 8 10 12 19971998199920002001200220032004 Year Incidence per 100 000 inhabitants

26. SWEDRES 2004 Swedres 2004, Figure 4.2. Overall national resistance rates of S.pneumoniae (resistant isolates in percent of all pneumococcal isolates) for four different antibiotics 1994–2004 (data from the annual RSQC programme, approximately 3000 isolates per year). 0 2 4 6 8 10 Penicillin I+R (oxa screen) ErythromycinTetracyclineTrimethoprim- sulfonamide % R 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004

27. SWEDRES 2004 Swedres 2004, Figure 4.3. Frequencies of reduced susceptibility to penicillin among invasive isolates of Streptococcus pneumoniae in Europe 2004. Data from EARSS (www.earss.rivm.nl 2005-04-25).www.earss.rivm.nl

28. SWEDRES 2004 Swedres 2004, Table 4.1. Susceptibility to penicillin and erythromycin among Swedish invasive isolates of Streptococcus pneumoniae reported to EARSS.

29. SWEDRES 2004 Swedres 2004, Table 4.2. MRSA notified in 2000-2004 by county according to the Commuicable Disease Act

30. SWEDRES 2004 No. of isolates with identical or related patterns (% of total) PFGE patternST of reference patterns 20002001200220032004 UK E152222 (9.1)76 (18.4)107 (24.4)119 (22.8)104 (16.9) DK E97-18043 (17.8)54 (13.1)73 (16.7)80 (15.4)94 (15.3) Berlin IV4523 (9.5)51 (12.4)14 (3.2)63 (12.1)72 (11.7) Bel EC-3a511 (4.5)18 (4.4)30 (6.8)46 (8.8)38 (6.2) UK E16 3633 (13.6)48 (11.7)41 (9.4)30 (5.8)49 (8.0) UK E1 / Spa E1 / Gr-1 239, 24131 (12.8)29 (7.0)35 (8.0)18 (3.5)20 (3.3) Fra A827 (11.2)31 (7.5)28 (6.4)20 (3.8)13 (2.1) Fra B83 (1.2)18 (4.4)16 (3.7)27 (5.2)47 (7.6) UK E354 (1.7)10 (2.4)13 (3.0)15 (2.9)29 (4.7) S German II2284 (1.7)5 (1.2)8 (1.8)7 (1.3)6 (1.0) Unrelated SE- patterns 30 (12.4)52 (12.6)62 (14.2)79 (15.2)123 (20.0) UniqueNot tested11 (4.5)20 (4.9)11 (2.5)17 (3.3)29 (4.7) Total 242412438521615 Swedres 2004, Table 4.3. PFGE patterns of MRSA isolated in Sweden 2000-2004

31. SWEDRES 2004 Swedres 2004, Figure 4.5. Resistance rates for Staphylococcus aureus 2001-2004 (data from the annual RSQC programme, approximately 3000 isolates per year).

32. SWEDRES 2004 Swedres 2004, Figure 4.6. MRSA in Europé 2004. Data from EARSS (www.earss.rivm.nl 2005-04-25)www.earss.rivm.nl

33. SWEDRES 2004 Swedres 2004, Table 4.4. Staphylococcus aureus susceptibility results (number of strains and percentage) using the oxacillin disk diffusion method according to SRGA in Sweden. Data reported from SMI to EARSS.

34. SWEDRES 2004 Swedres 2004, Figure 4.7. Annual number of VRE cases reported in Sweden.

35. SWEDRES 2004 Swedres 2004, Figure 4.8. Reported cases of VRE in selected counties from 2000 to 2004

36. SWEDRES 2004 Swedres 2004, Figure 4.9. Resistance rates of E. Faecalis, 1994, 1997, 2004, RSQC programme.

37. SWEDRES 2004 Swedres 2004, Figure 4.10. Resistance rates (resistant isolates in percent of all Escherichia coli isolates) for six different antibiotics 1996-2004.

38. SWEDRES 2004 Swedres 2004, Figure 4.11. Resistance rates (% R and I) to fluoroquinolones in Escherichia coli in Europe 2004.

39. SWEDRES 2004 Swedres 2004, Figure 4.12. Resistance rates (resistant isolates in percent of all Pseudomonas aeruginosa isolates) for six different antibiotics 1984- 2004.

40. SWEDRES 2004 Swedres 2004, Figure 4.13. Proportion of patients with resistant TB (resistant to at least one of the first line drugs).